SCHEMBL5405508

SCHEMBL5405508

CCN(CC)CCNC(=O)Cc1c(C)[nH]c(C=O)c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 13/20 0.41
PRKAA1 Q13131 9/20 0.41
PDGFRB P09619 7/20 0.41
PRKAA2 P54646 7/20 0.41
FGFR1 P11362 5/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.40
EGFR P00533 5/20 0.39
FLT3 P36888 4/20 0.39
CSF1R P07333 3/20 0.39
KIT P10721 3/20 0.39
PLK4 O00444 2/20 0.39
DCLK1 O15075 2/20 0.39
PDPK1 O15530 2/20 0.39
DAPK3 O43293 2/20 0.39
ROCK2 O75116 2/20 0.39
RPS6KA5 O75582 2/20 0.39
RPS6KA4 O75676 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1044420 0.80 KDR (0.59) KDRPRKAA1PDGFRBPRKAA2FGFR1
SCHEMBL1312585 0.80 KDR (0.52) KDRPRKAA1PDGFRBPRKAA2FGFR1
SCHEMBL13356509 0.76 KDR (0.45) KDRPRKAA1PDGFRBPRKAA2FGFR1
SCHEMBL6088559 0.76 KDR (0.46) KDRPRKAA1PDGFRBPRKAA2FGFR1
SCHEMBL11904724 0.76 KDR (0.41) KDRPRKAA1PDGFRBPRKAA2FGFR1
SCHEMBL6089467 0.76 KDM4E (0.37) KDRKMT2AKDM4EALDH1A1CHEK1
SCHEMBL5401668 0.75 L3MBTL1 (0.45) KDRPDGFRBFGFR1MEN1KMT2A
SCHEMBL6091127 0.75 KDR (0.40) KDRPRKAA1PDGFRBPRKAA2FGFR1
SCHEMBL6088913 0.74 KDR (0.39) KDRPRKAA1PDGFRBPRKAA2FGFR1
SCHEMBL12906990 0.73 KDR (0.53) KDRPRKAA1PDGFRBPRKAA2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) SUGEN, INC. 2004-12-30 US disclosed
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors DMPK, MAP3K20, PHKG1 KDR 1657/4885PRKAA1 114/4885PDGFRB 913/4885
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) CHEK2, CHEK1, ATM KDR 1541/4885PRKAA1 348/4885PDGFRB 1414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.